Advertisement

Additive interaction between scopolamine and nitric oxide agents on immobility in the forced swim test but not exploratory activity in the hole-board

  • Mohammad Nasehi
  • Mohammad-Hossein Mohammadi-Mahdiabadi-Hasani
  • Mohaddeseh Ebrahimi-GhiriEmail author
  • Mohammad-Reza Zarrindast
Original Investigation
  • 50 Downloads

Abstract

Rationale

The muscarinic cholinergic antagonist scopolamine has received an attention due to its unique antidepressant effects. However, the considerable adverse effects on nervous system limit the use of scopolamine as a psychiatric drug.

Objective

In order to overcome the limitations and increase the therapeutic effects of scopolamine, we decided to examine the effects of joint administration of sub-effective dose of scopolamine and the sub-effective dose of a nitric oxide (NO) precursor l-Arginine or a non-selective nitric oxide synthase (NOS) inhibitor l-NAME on depression- and anxiety-related behaviors in male NMRI mice.

Methods

To this aim, animal behavior was assessed in the forced swim test (FST) and hole-board apparatus.

Results

Scopolamine (0.05 mg/kg) significantly decreased immobility time in the FST, suggesting an antidepressant-like effect. Moreover, l-Arginine (50 mg/kg) produced an antidepressant-like response in the FST and decreased head-dip counts in the hole-board apparatus, indicating an anxiety-like effect. The same doses of scopolamine and l-Arginine decreased the locomotor activity in mice. Joint administration of sub-effective dose of scopolamine (0.01 mg/kg) with a low dose of l-Arginine (25 mg/kg) or l-NAME (1 mg/kg) induced a profound antidepressant-like effect in the FST. These drug combinations did not influence on anxiety-related behaviors. Meanwhile, l-NAME alone did not alter the performance of mice in the FST and hole-board. Isobolographic analysis revealed an additive effect for scopolamine and l-Arginine or l-NAME.

Conclusion

Data suggests that NO agents could positively impact the therapeutic profile of scopolamine, because they might be useful for inducing antidepressant-like effect associated to scopolamine.

Keywords

Scopolamine l-Arginine l-NAME Depression- and anxiety-related behaviors Mice 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

213_2019_5294_MOESM1_ESM.pdf (380 kb)
ESM 1 (PDF 379 kb)

References

  1. Ali AK, Banks WA, Kumar VB, Shah GN, Lynch JL, Farr SA, Fleegal-DeMotta MA, Morley JE (2009) Nitric oxide activity and isoenzyme expression in the senescence-accelerated mouse p8 model of Alzheimer’s disease: effects of anti-amyloid antibody and antisense treatments. J Gerontol A Biol Sci Med Sci 64:1025–1030.  https://doi.org/10.1093/gerona/glp074 CrossRefGoogle Scholar
  2. Alijanpour S, Khakpai F, Ebrahimi-Ghiri M, Zarrindast M-R (2019) Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice. Biomed Pharmacother 109:589–594.  https://doi.org/10.1016/j.biopha.2018.10.033 CrossRefGoogle Scholar
  3. Aracri P, Consonni S, Morini R, Perrella M, Rodighiero S, Amadeo A, Becchetti A (2010) Tonic modulation of GABA release by nicotinic acetylcholine receptors in layer V of the murine prefrontal cortex. Cereb Cortex 20:1539–1555.  https://doi.org/10.1093/cercor/bhp214 CrossRefGoogle Scholar
  4. Baek I-S, Park J-Y, Han P-L (2015) Chronic antidepressant treatment in normal mice induces anxiety and impairs stress-coping ability. Exp Neurobiol 24:156–168.  https://doi.org/10.5607/en.2015.24.2.156 CrossRefGoogle Scholar
  5. Barik J, Wonnacott S (2006) Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol Pharmacol 69:618–628.  https://doi.org/10.1124/mol.105.018184 CrossRefGoogle Scholar
  6. Beiranvand F, Zlabinger C, Orr-Urtreger A, Ristl R, Huck S, Scholze P (2014) Nicotinic acetylcholine receptors control acetylcholine and noradrenaline release in the rodent habenulo-interpeduncular complex. Br J Pharmacol 171:5209–5224.  https://doi.org/10.1111/bph.12841 CrossRefGoogle Scholar
  7. Borda T, Genaro A, Sterin-Borda L, Cremaschi G (1998) Involvement of endogenous nitric oxide signalling system in brain muscarinic acetylcholine receptor activation. J Neural Transm 105:193–204.  https://doi.org/10.1007/s007020050048 CrossRefGoogle Scholar
  8. Bortz DM, Mikkelsen JD, Bruno JP (2013) Localized infusions of the partial alpha 7 nicotinic receptor agonist SSR180711 evoke rapid and transient increases in prefrontal glutamate release. Neuroscience 255:55–67.  https://doi.org/10.1016/j.neuroscience.2013.09.047 CrossRefGoogle Scholar
  9. Bugajski AJ, Gadek-Michalska A, Bugajski J (2006) The involvement of nitric oxide and prostaglandins in the cholinergic stimulation of hypothalamie-pituitary-adrenal response during crowding stress. J Physiol Pharmacol 57:463–477Google Scholar
  10. Calixto AV, Duarte FS, Duzzioni M, Nascimento Häckl LP, Faria MS, de Lima TCM (2010) Role of ventral hippocampal nitric oxide/cGMP pathway in anxiety-related behaviors in rats submitted to the elevated T-maze. Behav Brain Res 207:112–117.  https://doi.org/10.1016/j.bbr.2009.09.037 CrossRefGoogle Scholar
  11. da Silva GD, Matteussi AS, dos Santos AR et al (2000) Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Neuroreport 11:3699–3702CrossRefGoogle Scholar
  12. de Oliveira RM, Aparecida Del Bel E, Mamede-Rosa ML et al (2000) Expression of neuronal nitric oxide synthase mRNA in stress-related brain areas after restraint in rats. Neurosci Lett 289:123–126CrossRefGoogle Scholar
  13. Del Bel EA, Guimaraes FS, Bermudez-Echeverry M et al (2005) Role of nitric oxide on motor behavior. Cell Mol Neurobiol 25:371–392CrossRefGoogle Scholar
  14. Deshpande SR, Satyanarayana K, Rao MNA, Pai KV (2012) Nitric oxide modulators: an emerging class of medicinal agents. Indian J Pharm Sci 74:487–497.  https://doi.org/10.4103/0250-474X.110572 CrossRefGoogle Scholar
  15. Dhir A, Kulkarni SK (2011) Nitric oxide and major depression. Nitric Oxide - Biol Chem 24:125–131.  https://doi.org/10.1016/j.niox.2011.02.002 CrossRefGoogle Scholar
  16. Dougherty JJ, Nichols RA (2009) Cross-regulation between colocalized nicotinic acetylcholine and 5-HT3 serotonin receptors on presynaptic nerve terminals. Acta Pharmacol Sin 30:788–794.  https://doi.org/10.1038/aps.2009.62 CrossRefGoogle Scholar
  17. Dulawa SC, Janowsky DS (2018) Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. Mol Psychiatry 24:694–709.  https://doi.org/10.1038/s41380-018-0219-x CrossRefGoogle Scholar
  18. Ergun Y, Ergun UGO (2007) Prevention of pro-depressant effect of L-arginine in the forced swim test by NG-nitro-L-arginine and [1H-[1,2,4]Oxadiazole[4,3-a]quinoxalin-1-one]. Eur J Pharmacol 554:150–154.  https://doi.org/10.1016/j.ejphar.2006.09.067 CrossRefGoogle Scholar
  19. Forestiero D, Manfrim CM, Guimaraes FS, de Oliveira RMW (2006) Anxiolytic-like effects induced by nitric oxide synthase inhibitors microinjected into the medial amygdala of rats. Psychopharmacology 184:166–172.  https://doi.org/10.1007/s00213-005-0270-6 CrossRefGoogle Scholar
  20. Furey ML, Khanna A, Hoffman EM, Drevets WC (2010) Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 35:2479–2488.  https://doi.org/10.1038/npp.2010.131 CrossRefGoogle Scholar
  21. Garduno J, Galindo-Charles L, Jimenez-Rodriguez J, Galarraga E, Tapia D, Mihailescu S, Hernandez-Lopez S (2012) Presynaptic alpha4beta2 nicotinic acetylcholine receptors increase glutamate release and serotonin neuron excitability in the dorsal raphe nucleus. J Neurosci 32:15148–15157.  https://doi.org/10.1523/JNEUROSCI.0941-12.2012 CrossRefGoogle Scholar
  22. Garthwaite J, Garthwaite G, Palmer RM, Moncada S (1989) NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 172:413–416CrossRefGoogle Scholar
  23. Ghasemi M, Claunch J, Niu K (2019) Pathologic role of nitrergic neurotransmission in mood disorders. Prog Neurobiol 173:54–87.  https://doi.org/10.1016/j.pneurobio.2018.06.002 CrossRefGoogle Scholar
  24. Ghosal S, Bang E, Yue W, Hare BD, Lepack AE, Girgenti MJ, Duman RS (2018) Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine. Biol Psychiatry 83:29–37.  https://doi.org/10.1016/j.biopsych.2017.06.017 CrossRefGoogle Scholar
  25. Gross C, Hen R (2004) The developmental origins of anxiety. Nat Rev Neurosci 5:545–552.  https://doi.org/10.1038/nrn1429 CrossRefGoogle Scholar
  26. Guimaraes FS, Beijamini V, Moreira FA et al (2005) Role of nitric oxide in brain regions related to defensive reactions. Neurosci Biobehav Rev 29:1313–1322.  https://doi.org/10.1016/j.neubiorev.2005.03.026 CrossRefGoogle Scholar
  27. Heiberg IL, Wegener G, Rosenberg R (2002) Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 134:479–484CrossRefGoogle Scholar
  28. Inan SY, Yalcin I, Aksu F (2004) Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation. Pharmacol Biochem Behav 77:457–464.  https://doi.org/10.1016/j.pbb.2003.12.024 CrossRefGoogle Scholar
  29. Iniguez SD, Vialou V, Warren BL, Cao JL, Alcantara LF, Davis LC, Manojlovic Z, Neve RL, Russo SJ, Han MH, Nestler EJ, Bolanos-Guzman CA (2010) Extracellular signal-regulated kinase-2 within the ventral tegmental area regulates responses to stress. J Neurosci 30:7652–7663.  https://doi.org/10.1523/JNEUROSCI.0951-10.2010 CrossRefGoogle Scholar
  30. Kalouda T, Pitsikas N (2015) The nitric oxide donor molsidomine induces anxiolytic-like behaviour in two different rat models of anxiety. Pharmacol Biochem Behav 138:111–116.  https://doi.org/10.1016/j.pbb.2015.09.004 CrossRefGoogle Scholar
  31. Karolewicz B, Paul IA, Antkiewicz-Michaluk L (2001) Effect of NOS inhibitor on forced swim test and neurotransmitters turnover in the mouse brain. Pol J Pharmacol 53:587–596Google Scholar
  32. Kenny PJ, File SE, Neal MJ (2000) Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem 75:2409–2414CrossRefGoogle Scholar
  33. Khakpoor M, Nasehi M, Vahdati A, Hoseyni SE, Zarrindast MR (2016) Additive effect of BLA GABAAreceptor mechanism and (+)-MK-801 on memory retention deficit, an isobologram analysis. Pharmacol Biochem Behav 143:57–64.  https://doi.org/10.1016/j.pbb.2016.02.001 CrossRefGoogle Scholar
  34. Kim J, Isokawa M, Ledent C, Alger BE (2002) Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci 22:10182–10191CrossRefGoogle Scholar
  35. Klinkenberg I, Blokland A (2010) The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 34:1307–1350.  https://doi.org/10.1016/j.neubiorev.2010.04.001 CrossRefGoogle Scholar
  36. Kopf SR, Benton RS, Kalfin R, Giovannini MG, Pepeu G (2001) NO synthesis inhibition decreases cortical ACh release and impairs retention of a conditioned response. Brain Res 894:141–144CrossRefGoogle Scholar
  37. Kruk-Slomka M, Michalak A, Biala G (2015) Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system. Behav Brain Res 284:24–36.  https://doi.org/10.1016/j.bbr.2015.01.051 CrossRefGoogle Scholar
  38. Kurt M, Bilge SS, Aksoz E, Kukula O, Celik S, Kesim Y (2004) Effect of sildenafil on anxiety in the plus-maze test in mice. Pol J Pharmacol 56:353–357Google Scholar
  39. Li DP, Pan YZ, Pan HL (2001) Acetylcholine attenuates synaptic GABA release to supraoptic neurons through presynaptic nicotinic receptors. Brain Res 920:151–158CrossRefGoogle Scholar
  40. Lin Y-G, Chen P-H, Chang F-Y, Wu LT, Liao KY, Wu TC (2011) Delirium due to scopolamine patch in a 4-year-old boy. J Formos Med Assoc 110:208–211.  https://doi.org/10.1016/S0929-6646(11)60031-4 CrossRefGoogle Scholar
  41. Machawal L, Kumar A (2014) Possible involvement of nitric oxide mechanism in the neuroprotective effect of rutin against immobilization stress induced anxiety like behaviour, oxidative damage in mice. Pharmacol Rep 66:15–21.  https://doi.org/10.1016/j.pharep.2013.08.001 CrossRefGoogle Scholar
  42. Maggi L, Sher E, Cherubini E (2001) Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus. J Physiol 536:89–100CrossRefGoogle Scholar
  43. Mancinelli A, Borsini F, d’Aranno V et al (1988) Cholinergic drug effects on antidepressant-induced behaviour in the forced swimming test. Eur J Pharmacol 158:199–205CrossRefGoogle Scholar
  44. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244CrossRefGoogle Scholar
  45. Morato GS, Ortiga RM, Ferreira VMM (2004) Involvement of nitric oxide-dependent pathways of dorsolateral periaqueductal gray in the effects of ethanol in rats submitted to the elevated plus-maze test. Behav Brain Res 153:341–349.  https://doi.org/10.1016/j.bbr.2003.12.010 CrossRefGoogle Scholar
  46. Ostadhadi S, Norouzi-Javidan A, Nikoui V, Zolfaghari S, Moradi A, Dehpour AR (2018) Nitric oxide involvement in additive antidepressant-like effect of agmatine and lithium in mice forced swim test. Psychiatry Res 266:262–268.  https://doi.org/10.1016/j.psychres.2018.03.010 CrossRefGoogle Scholar
  47. Palucha-Poniewiera A, Podkowa K, Lenda T, Pilc A (2017) The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test. Prog Neuro-Psychopharmacol Biol Psychiatry 79:155–161.  https://doi.org/10.1016/j.pnpbp.2017.06.022 CrossRefGoogle Scholar
  48. Petryshen TL, Lewis MC, Dennehy KA, Garza JC, Fava M (2016) Antidepressant-like effect of low dose ketamine and scopolamine co-treatment in mice. Neurosci Lett 620:70–73.  https://doi.org/10.1016/j.neulet.2016.03.051 CrossRefGoogle Scholar
  49. Pistell PJ, Daffin LWJ, Nelson CM et al (2007) Combined administration of subthreshold doses of the nitric oxide inhibitor, nitro-L-arginine, and muscarinic receptor antagonist, scopolamine, impairs complex maze learning in rats. Behav Pharmacol 18:801–805.  https://doi.org/10.1097/FBP.0b013e3282f18d2f CrossRefGoogle Scholar
  50. Podkowa K, Podkowa A, Sałat K, Lenda T, Pilc A, Pałucha-Poniewiera A (2016) Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. Neuropharmacology 111:169–179.  https://doi.org/10.1016/j.neuropharm.2016.08.031 CrossRefGoogle Scholar
  51. Podkowa K, Pilc A, Podkowa A, Sałat K, Marciniak M, Pałucha-Poniewiera A (2018) The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice. Neuropharmacology 141:214–222.  https://doi.org/10.1016/j.neuropharm.2018.08.022 CrossRefGoogle Scholar
  52. Reno LAC, Zago W, Markus RP (2004) Release of [(3)H]-L-glutamate by stimulation of nicotinic acetylcholine receptors in rat cerebellar slices. Neuroscience 124:647–653.  https://doi.org/10.1016/j.neuroscience.2003.12.023 CrossRefGoogle Scholar
  53. Roohbakhsh A, Moghaddam AH, Massoudi R, Zarrindast M-R (2007) Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clin Exp Pharmacol Physiol 34:223–229.  https://doi.org/10.1111/j.1440-1681.2007.04576.x CrossRefGoogle Scholar
  54. Schwartz RD, Lehmann J, Kellar KJ (1984) Presynaptic nicotinic cholinergic receptors labeled by [3H]acetylcholine on catecholamine and serotonin axons in brain. J Neurochem 42:1495–1498CrossRefGoogle Scholar
  55. Sestakova N, Puzserova A, Kluknavsky M, Bernatova I (2013) Determination of motor activity and anxiety-related behaviour in rodents: methodological aspects and role of nitric oxide. Interdiscip Toxicol 6:126–135.  https://doi.org/10.2478/intox-2013-0020 CrossRefGoogle Scholar
  56. Sharples CG, Kaiser S, Soliakov L et al (2000) UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 20:2783–2791CrossRefGoogle Scholar
  57. Singh P, Singh TG (2015) Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice. Indian J Pharmacol 47:388–393.  https://doi.org/10.4103/0253-7613.161260 CrossRefGoogle Scholar
  58. Small KM, Nunes E, Hughley S, Addy NA (2016) Ventral tegmental area muscarinic receptors modulate depression and anxiety-related behaviors in rats. Neurosci Lett 616:80–85.  https://doi.org/10.1016/j.neulet.2016.01.057 CrossRefGoogle Scholar
  59. Spiacci AJ, Kanamaru F, Guimaraes FS, Oliveira RMW (2008) Nitric oxide-mediated anxiolytic-like and antidepressant-like effects in animal models of anxiety and depression. Pharmacol Biochem Behav 88:247–255.  https://doi.org/10.1016/j.pbb.2007.08.008 CrossRefGoogle Scholar
  60. Sugaya K, McKinney M (1994) Nitric oxide synthase gene expression in cholinergic neurons in the rat brain examined by combined immunocytochemistry and in situ hybridization histochemistry. Brain Res Mol Brain Res 23:111–125CrossRefGoogle Scholar
  61. Takeda H, Tsuji M, Matsumiya T (1998) Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 350:21–29CrossRefGoogle Scholar
  62. Udayabanu M, Kumaran D, Nair RU, Srinivas P, Bhagat N, Aneja R, Katyal A (2008) Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res 1230:138–149.  https://doi.org/10.1016/j.brainres.2008.06.081 CrossRefGoogle Scholar
  63. Utkan T, Gocmez SS, Regunathan S, Aricioglu F (2012) Agmatine, a metabolite of L-arginine, reverses scopolamine-induced learning and memory impairment in rats. Pharmacol Biochem Behav 102:578–584.  https://doi.org/10.1016/j.pbb.2012.07.003 CrossRefGoogle Scholar
  64. Voleti B, Navarria A, Liu R-J, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS (2013) Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 74:742–749.  https://doi.org/10.1016/j.biopsych.2013.04.025 CrossRefGoogle Scholar
  65. Wegener G, Volke V (2010) Nitric oxide synthase inhibitors as antidepressants. Pharmaceuticals 3:273–299.  https://doi.org/10.3390/ph3010273 CrossRefGoogle Scholar
  66. Wohleb ES, Wu M, Gerhard DM, Taylor SR, Picciotto MR, Alreja M, Duman RS (2016) GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. J Clin Invest 126:2482–2494.  https://doi.org/10.1172/JCI85033 CrossRefGoogle Scholar
  67. Zarrindast M-R, Nasehi M, Khansari M, Bananej M (2011a) Influence of nitric oxide agents in the rat amygdala on anxiogenic-like effect induced by histamine. Neurosci Lett 489:38–42.  https://doi.org/10.1016/j.neulet.2010.11.062 CrossRefGoogle Scholar
  68. Zarrindast MR, Nasehi M, Piri M, Heidari N (2011b) Effects of cholinergic system of dorsal hippocampus of rats on MK-801 induced anxiolytic-like behavior. Neurosci Lett 505:65–70.  https://doi.org/10.1016/j.neulet.2011.08.009 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Mohammad Nasehi
    • 1
  • Mohammad-Hossein Mohammadi-Mahdiabadi-Hasani
    • 2
  • Mohaddeseh Ebrahimi-Ghiri
    • 3
    Email author
  • Mohammad-Reza Zarrindast
    • 2
    • 4
    • 5
    • 6
  1. 1.Cognitive and Neuroscience Research Center (CNRC), Tehran Medical Sciences, Amir-Almomenin HospitalIslamic Azad UniversityTehranIran
  2. 2.Institute for Cognitive Science Studies (ICSS)TehranIran
  3. 3.Department of Biology, Faculty of SciencesUniversity of ZanjanZanjanIran
  4. 4.Department of Pharmacology School of MedicineTehran University of Medical SciencesTehranIran
  5. 5.Iranian National Center for Addiction StudiesTehran University of Medical SciencesTehranIran
  6. 6.Department of Neuroendocrinology, Endocrinology, and Metabolism Research InstituteTehran University of Medical SciencesTehranIran

Personalised recommendations